α-Galactosylceramide

α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor) [1][2][3][4].

Product Specifications

CAS Number

[158021-47-7]

Product Name Alternative

α-GalCer; KRN7000

UNSPSC

12352005

Hazard Statement

H315, H319

Target

CD1; Interleukin Related; Transmembrane Glycoprotein

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/alpha-galactosylceramide.html

Purity

95.85

Solubility

DMSO : 0.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCCCCCCCCCCCCCCCCCCCCCCCCC(N[C@@H](CO[C@@H]1[C@@H]([C@H]([C@H]([C@@H](CO)O1)O)O)O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)=O

Molecular Formula

C50H99NO9

Molecular Weight

858.34

Precautions

H315, H319

References & Citations

[1]Godfrey DI, et al. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest. 2004 Nov;114 (10) :1379-88.|[2]Morita M, et al. Practical Total Synthesis of (2S,3S,4R) -1-O- (α-D-Galactopyranosyl) -N-hexacosanoyl-2-amino-1,3,4-octadecanetriol, the Antitumorial and Immunostimulatory α-Galactosylcer-amide, KRN7000. Biosci Biotechnol Biochem. 1996 Jan;60 (2) :288-92.|[3]Kikuchi A, et al. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Br J Cancer. 2001 Sep 1;85 (5) :741-6.|[4]Masahiro Morita, et al. Structure-Activity Relationship of .alpha.-Galactosylceramides against B16-Bearing Mice. J. Med. Chem. 1995, 38, 12, 2176-2187.